Academic literature on the topic 'Francesco Della Torre'

Background:Patients with severe COVID-19 pneumonia and hyperinflammation face increased mortality. There is an urgent need for effective treatments to reduce the burden of the COVID-19 pandemic.Objectives:Our protocol aimed at evaluating the potential improvement in clinical outcomes with mavrilimumab, an anti-Granulocyte/Macrophage Colony-Stimulating Factor Receptor alpha (GM-CSFRα) monoclonal antibody, in patients with COVID-19 pneumonia and systemic hyper-inflammation.Methods:Single-center, open-label, single active arm intervention; Adult patients with severe COVID-19 pneumonia (as evaluated by CT scanning), hypoxia (PaO2:FiO2 ratio ≤ 300 mmHg), and systemic hyper-inflammation (increased C-reactive protein [CRP] ≥ 100 mg/mL and/or ferritin ≥ 900 μg/L, increased lactate dehydrogenase [LDH]) received a single intravenous dose of mavrilimumab added to standard of care; follow-up 28 days. Main outcomes measure was time to clinical improvement (reduction ≥ 2 categories on the 7-point WHO clinical status scale, 1=discharge, 7=death); others included time to discharge from hospital; % of pts achieving a clinical improvement; survival; mechanical-ventilation free survival; time to fever resolution; CRP; PaO2:FiO2 ratio.Results:A mavrilimumab group (n=13 COVID-19 patients, non-mechanically ventilated, median age 57 [IQR, 52-58], males 12 [92%], febrile 11 [85%]; PaO2:FiO2195.5[166.7–215.0]) was compared to a cohort of 26 contemporaneous patients with similar baseline characteristics. Death occurred in 0% (n=0/13) of mavrilimumab recipients and 27% (n=7/26) of comparison-group patients (log rank p=0.046) during the 28-day follow-up. 100% (n=13) of mavrilimumab recipients and 65% (n=17) of comparison-group patients achieved clinical improvement (p=0.018) at Day 28, with earlier improvement (median 8.0 [IQR, 5.0–11.0] days vs 18.5 [11.0–NE] days) (p<0.001) in mavrilimumab recipients. Fever had resolved in 91% (n=10/11 febrile patients) of mavrilimumab recipients by Day 14, compared to 61% (n=11/18 febrile) of patients in the comparison group (p=0.110); fever resolution was faster in mavrilimumab recipients versus controls (median 1.0 [IQR, 1.0–2.0] day vs 7.0 [3.0 - NE] days, respectively, p=0·009). Mavrilimumab was well tolerated in all patients.Conclusion:Patients with severe COVID-19 pneumonia and systemic hyper-inflammation who received treatment with mavrilimumab had better clinical outcomes compared to patients receiving routine care. Mavrilimumab was well-tolerated. Randomized controlled trials are warranted to confirm our findings.References:[1]Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62[2]Mehta P, McAuley DF, Brown M, et al. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-4Disclosure of Interests:Giacomo De Luca Speakers bureau: SOBI, Novartis, Celgene, Pfizer, MSD, Giulio Cavalli Speakers bureau: SOBI, Novartis, Pfizer, Corrado Campochiaro Speakers bureau: Novartis, Pfizer, Roche, GSK, SOBI, Emanuel Della Torre: None declared, Piera Angelillo: None declared, Alessandro Tomelleri: None declared, nicola boffini: None declared, Stefano Tentori: None declared, Francesca Mette: None declared, Patrizia Rovere-Querini: None declared, Annalisa Ruggeri: None declared, Teresa D’Aliberti: None declared, Paolo Scarpelllini: None declared, Giovanni Landoni: None declared, Francesco De Cobelli: None declared, John F. Paolini Shareholder of: Kiniksa, Employee of: Kiniksa, Alberto Zangrillo: None declared, Moreno Tresoldi: None declared, Bruce C. Trapnell Consultant of: Kiniksa, Fabio Ciceri: None declared, Lorenzo Dagna Grant/research support from: Abbvie, BMS, Celgene, Janssen, MSD, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, SG, SOBI, Consultant of: Abbvie, Amgen, Biogen, BMS, Celltrion, Novartis, Pfizer, Roche, SG, and SOBI

FLAVIA LAVIOSA IN CONVERSATION WITH ITALIAN DIRECTOR CRISTINA COMENCINI A PROLIFIC film director and screenplay writer as well as an accomplished novelist, Cristina Comencini (1956) is well known for her novels and her numerous films. Together with Francesca Archibugi (1960) and Roberta Torre (1962), she is one of the new Italian filmmakers who, in the last sixteen years, have become famous for having put forward new assertive female characters in cinema, thanks also to a good commercial distribution of her works. Comencini's films, Zoo (1988); I divertimenti della vita privata (Amusements of the Private Life, 1990); La fine è nota (The End Is Known, 1992); Va' dove ti porta il cuore (Follow Your Heart, 1996); Matrimoni (Marriages, 1998); Liberate I pesci! (Free the Fish!, 1999); Il più bel giorno della mia vita (The Best Day of My Life, 2002); La bestia nel cuore (The Beast In the Heart, 2005);...

Questa tesi ricostruisce il contributo di Francesco Maria Grimaldi alla comprensione del fenomeno di diffrazione, da lui sperimentalmente studiato per la prima volta nella seconda metà del Seicento. Il primo capitolo di questo elaborato vuole mostrare i contributi offerti da Grimaldi all’astronomia e alla geodesia in collaborazione con Ricciòli, gesuita e astronomo bolognese, ed anche il rapporto tra scienza e fede, in particolare tra i Gesuiti e l’Università di Bologna. Il secondo capitolo è focalizzato sul De lumine, opera postuma di Grimaldi, e sui due esperimenti riguardanti la diffrazione ivi contenuti. Il terzo capitolo viene dedicato alla storia della diffrazione analizzando la trattazione che ne fecero gli scienziati dopo Grimaldi: si parte da Newton e dalla sua visione corpuscolare della luce per arrivare ad Huygens, Young e Fresnel e all’elaborazione della teoria ondulatoria, che permette di spiegare correttamente il fenomeno della diffrazione.

Girolamo completes his sentence in mid-1559, and the family moves into the bishop’s castle in Ceneda, and then on to the castle at Villalta. Giulia furnishes each residence, as well as Palazzo Torriani in Udine, with trappings and furniture suitable to the family’s noble status. Giovanni da Udine embellishes the ceiling of a studiolo in the Castello di Colloredo with grotteschi decoration. While the Della Torre stay out of trouble, their Colloredo relatives keep the blood feud alive. After bearing two more daughters, Ginevra and Elena, Giulia is pregnant again and prophesies her own death. She dies in Ceneda in spring 1562 shortly after giving birth to Giulia II, her tenth child, ‘renewing the major part of the ancestors and herself’. The bloodline was secure. Francesco Sansovino honours Giulia in 1565 with the first freestanding female biography of an ordinary woman to appear in print in Renaissance Italy.

The Tower of San Francesco in Palmi in the views of Edward Cheney of 1823: images of a disappeared bulwark of the viceregal defensive system of Calabria UltraTo oppose the phenomenon of waves of Turks threatening the most exposed areas of the Kingdom of Naples, the viceregal government ordered from 1535 the construction of a continuous and articulated chain of defensive coastal towers. In Calabria, on behalf of the Viceroy Pedro di Toledo, the Marquis Francesco Pignatelli developed a project to identify the most suitable and strategic sites where to build the towers along the Tyrrhenian and Ionian coasts. This network included 69 towers in Calabria Ultra and 33 in Calabria Citra, clearly visible from each other at a maximum distance of six thousand steps. Most of these towers have lost their original function over time, and after the taking of Algiers in 1830, some were used as customs posts or torri semaforiche, and then be permanently abandoned. Today almost all of them are ruins. The cartographic sources and above all the iconographic ones, testify the importance of this defensive system of towers suspended between the land and the sea and arranged one after the other, real sentinels of the Mediterranean. On this occasion, the focus is on the Tower of San Francesco, was probably built in 1565, in Capo Barbi in Palmi, along the Tyrrhenian side between Reggio Calabria and Capo Vaticano. The bulwark was destroyed in 1956. The Tower of San Francesco, as evidenced by historical cartography and the views of Antonio Minasi in 1779 and Richard Keppel Craven in 1821, was portrayed in three drawings made by Edward Cheney during his travel to Calabria in May 1823. These views identify the characteristics of the architectural typology of the tower and the relationships with the town of Palmi; to relate it to the coastal towers of Pietre Nere (Taureana) and Capo Rocchi (Bagnara); and finally to the landscape of the Costa Viola up to the Strait of Messina.